Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Retrieved on:
Wednesday, April 24, 2024
Oncology, Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, METIS, Efficacy, Safety, Patient, Deep learning, International, TIGER, Abstract, Survival, Metastasis, Lung cancer, MD, Baptist Health South Florida, Glioblastoma, ASCO, Radiation therapy, Pembrolizumab, Treatment, Brain, Society, Platinum, CDT, Clinical trial, Annual general meeting, Baptist Health, NSCLC, Medical imaging
METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC.
Key Points:
- METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC.
- “We are honored to present the results of the METIS clinical trial as a late-breaking abstract this year at ASCO, the largest global oncology conference,” said Asaf Danziger, Novocure’s Chief Executive Officer.
- “Patients with brain metastases from non-small cell lung cancer need more treatment options.
- The METIS trial demonstrated that TTFields Therapy delayed intracranial progression while preserving neurological function, which is critical for these underserved patients.